RxDoctor Payments Data

Theda Kontis, MD

Facial Plastic Surgery · Baltimore, MDNPI 1558479394

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,836 of the $15,765 with a category attached, or 75.1%. 8 manufacturers reported payments, led by AbbVie at 55.1% of the total. Reporting peaked in 2023 at $7,872 and has fallen 95.0% since, to $397 in 2025.

$15,765in general payments, 2019–2025

Across 94 payments — averaging $167.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Galderma Laboratories, L.p.$5K
  • Merz North America, Inc.$1K
  • Medtronic$150
  • Johnson & Johnson$139
  • Integra Lifesciences Corporation$133
  • plus $130 from 2 others
$96,313in research payments, 2019–2025

Across 21 payments — averaging $4586.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Galderma Laboratories, L.p.$92K
  • AbbVie$4K

What the payments were for

  • Consulting fees$11,83675%
  • Speaking & faculty fees$5003%
  • Food & beverage$3,42922%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few facial plastic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$48,207
Medicare patients
91
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine-PrilocaineLidocaine/Prilocaine54$586
ValacyclovirValacyclovir Hcl21$519
Cefadroxil29$104
Azithromycin11$28
Oxycodone Hcl14$28
Ondansetron OdtOndansetron12$18

Paid to pharmacies, not to this prescriber.

Other facial plastic surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →